Sign up to save your podcasts
Or
Share Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Grzegorz (Greg) Nowakowski, MD - Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
Go online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series of alternating case-based discussions and mini-lectures, the panelists use recent science to explore the practice of novel antibodies and CAR-T cell therapy, including: the identification of candidates for treatment with novel antibodies or cellular therapy; the principles of therapeutic sequencing; appropriate safety management and monitoring strategies; and the emergence of novel immunotherapy options in the form of bispecific antibodies. Upon completion of this CE activity, participants will be able to: Summarize the treatment role of novel antibodies and CAR-T options in the management of relapsed diffuse large b-cell lymphoma (DLBCL) as supported by current evidence and clinical practice guidelines, Integrate novel antibody and cellular therapy options, including as sequential therapy, in the management of patients with relapsed/refractory DLBCL, Manage practical considerations associated with antibody and cellular therapy in DLBCL, including confirmation of patient eligibility for treatment, referral to specialized care centers when appropriate, and strategies for mitigating or managing adverse events in patients receiving therapy.
View all episodes
By PVI, PeerView Institute for Medical Education
4.3
99 ratings
Go online to PeerView.com/GWN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The transformation of patient care in diffuse large b-cell lymphoma (DLBCL), driven by advances with antibodies and cellular therapy, continues—what will this mean for your practice? Find out in PeerView’s “Clinical Consults” video activity where a panel of DLBCL will focus on the applications of these dual innovations in the management of DLBCL. Using a series of alternating case-based discussions and mini-lectures, the panelists use recent science to explore the practice of novel antibodies and CAR-T cell therapy, including: the identification of candidates for treatment with novel antibodies or cellular therapy; the principles of therapeutic sequencing; appropriate safety management and monitoring strategies; and the emergence of novel immunotherapy options in the form of bispecific antibodies. Upon completion of this CE activity, participants will be able to: Summarize the treatment role of novel antibodies and CAR-T options in the management of relapsed diffuse large b-cell lymphoma (DLBCL) as supported by current evidence and clinical practice guidelines, Integrate novel antibody and cellular therapy options, including as sequential therapy, in the management of patients with relapsed/refractory DLBCL, Manage practical considerations associated with antibody and cellular therapy in DLBCL, including confirmation of patient eligibility for treatment, referral to specialized care centers when appropriate, and strategies for mitigating or managing adverse events in patients receiving therapy.
More shows like PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
View all
JAMA Editors' Summary
129 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
6 Listeners
Lung Cancer Update
31 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Gastroenterology CME/CNE/CPE Audio Podcast
3 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
10 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast
28 Listeners
PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
9 Listeners
PeerView Gastroenterology CME/CNE/CPE Video Podcast
3 Listeners
PeerView Internal Medicine CME/CNE/CPE Video Podcast
2 Listeners
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
5 Listeners
PeerView Endocrinology & Diabetes CME/CNE/CPE Video Podcast
3 Listeners
PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast
3 Listeners
PeerView Infectious Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Audio Podcast
5 Listeners
PeerView Kidney & Genitourinary Diseases CME/CNE/CPE Video Podcast
2 Listeners
PeerView Infectious Diseases CME/CNE/CPE Video Podcast
0 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast
9 Listeners
NEJM This Week
318 Listeners
Journal of Clinical Oncology (JCO) Podcast
42 Listeners
PeerView Immunology & Transplantation CME/CNE/CPE Video Podcast
2 Listeners
Research To Practice | Oncology Videos
114 Listeners
PeerView Clinical Pharmacology CME/CNE/CPE Video
2 Listeners
JAMA Clinical Reviews
484 Listeners
ASCO Daily News
55 Listeners
ASCO Guidelines
43 Listeners
OncLive® On Air
21 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
321 Listeners
Oncology Today with Dr Neil Love
54 Listeners
CCO Oncology Podcast
10 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners